Company Overview of Sprout Pharmaceuticals, Inc.
Sprout Pharmaceuticals, Inc. develops products for treatment of female sexual health. The company was founded in 2011 and is based in Raleigh, North Carolina.
4208 Six Forks Road
Raleigh, NC 27609
Founded in 2011
Key Executives for Sprout Pharmaceuticals, Inc.
Co-Founder and Chief Executive Officer
Compensation as of Fiscal Year 2015.
Sprout Pharmaceuticals, Inc. Key Developments
Sprout Pharmaceuticals Receives U.S. Food and Drug Administration Approval of Addyi (Flibanserin 100 mg)
Aug 18 15
Sprout Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has granted approval of Addyi (flibanserin 100 mg) (pronounced add-ee), a once-daily, non-hormonal pill for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. Addyi is the first and only FDA-approved treatment for this condition, the most common form of female sexual dysfunction, affecting up to 1 in 10 women in the United States. HSDD is defined as a persistent absence of sexual thoughts, fantasies, responsiveness and willingness to engage in sexual activity that causes personal or relationship distress and cannot be accounted for by another medical condition or substance. Acquired HSDD refers to HSDD that develops in a patient who previously had no problems with sexual desire. Generalized HSDD refers to HSDD that occurs regardless of the type of stimulation, situation or partner.
Sprout Pharmaceuticals, Inc. - Special Call
Aug 18 15
To discuss on U.S. Food and Drug Administration approval of Addyi™ (flibanserin 100 mg) (pronounced add-ee)
Sprout Pharmaceuticals Resubmits Flibanserin New Drug Application for The Treatment Of Hypoactive Sexual Desire Disorder In Premenopausal Women
Feb 17 15
Sprout Pharmaceuticals announced that it has resubmitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for flibanserin, an investigational, once-daily, non-hormonal pill for Hypoactive Sexual Desire Disorder (HSDD) in premenopausal women. If approved, flibanserin will be the first and only FDA-approved treatment for HSDD. Flibanserin was evaluated in three pivotal Phase 3, randomized, double-blind, placebo-controlled, parallel-group North American studies of premenopausal women with a mean age of 36 years. In all trials, flibanserin demonstrated a statistically significant difference compared to placebo on three key endpoints: an increase of sexual desire; a decrease in distress from the loss of sexual desire; and an increase in the frequency of satisfying sex.
Similar Private Companies By Industry
Recent Private Companies Transactions
August 20, 2015
May 22, 2015
Most Searched Private Companies
Sponsored Financial Commentaries